Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In the current fund-raising environment, focusing on rapid decision making, spreading risk across several assets and introducing innovative trial designs could pay dividends for biotech entrepreneurs.
As more startups share competitive business information in their search for partners within big pharma or biotech, what legal protections are available if their intellectual property is infringed upon?
Job security in big pharma is not what it once was. For those looking for a new challenge, a group of big company refugees recount their experience starting up a new life science venture.
When seeking a licensing partner for a product in development, market projections and strategies require substantiation. This can be provided through physician interviews.
In an industry with a lengthy product development timeline, capital efficiency is paramount. But successful capital-efficient strategies require a different approach to thinking, working and fundraising.